Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2021, with a specific reporting date of March 2, 2021. The document serves as a notification regarding the vesting of Deferred Annual Bonus Plan (DABP) awards granted in 2018 to Persons Discharging Managerial Responsibilities (PDMRs). The three-year restricted period for these awards concluded on March 1, 2021. The filing details the subsequent exercise of nil-cost options and the sale of Ordinary Shares and American Depositary Shares (ADSs) to satisfy tax liabilities.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics for the company. It focuses exclusively on executive compensation transactions. Key market data points provided include:
- Ordinary Share Closing Price (March 1, 2021): £12.0060
- ADS Closing Price (March 1, 2021): $33.73
- Transaction Prices: Shares were exercised at £0.00 (nil-cost) and sold at market prices ranging from £12.0992 to £12.1132 for Ordinary Shares, and $33.7970 for ADSs.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely reports the routine vesting of equity awards and associated tax-related sales by eight senior executives. These transactions are consistent with the 2017 Remuneration Policy and the DABP rules.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a regulatory disclosure of specific share transactions.
Important Facts for Investors
- Executive Transactions: The filing details transactions for eight PDMRs, including CEO Emma Walmsley, President of Global Vaccines Richard Connor, and President of Global Pharmaceuticals Luc Miels.
- Transaction Nature: All transactions involved the vesting of nil-cost options or restricted awards granted in 2018, followed by immediate sales to cover tax obligations.
- Volume of Shares:
- Emma Walmsley: 68,716 shares vested; 32,346 shares sold.
- Richard Connor: 14,551 shares vested; 6,857 shares sold.
- Luc Miels: 13,820 shares vested; 6,501 shares sold.
- Other executives (Hirons, McNamara, Redfern, Terrell, Thomson) had smaller volumes ranging from 2,480 to 9,555 shares vested.
- Market Context: The sales occurred at prices slightly above the closing market price on March 1, 2021, reflecting intraday trading values.